ProSomnus® Sleep Technologies
Showcased in Key Poster Abstracts at the 2019 AADSM Annual Meeting
ProSomnus Sleep Technologies is the Leader in Precision Oral Appliance Therapy for OSA
San Francisco, CA, June 4, 2019 – ProSomnus Sleep Technologies devices will be showcased in at least five poster abstracts at the upcoming AADSM Annual Meeting, June 7-9 in San Antonio, TX. ProSomnus is committed to evidence-based research that enables clinicians to provide the best patient experiences and outcomes for OSA therapy.
Some of the highlighted posters include:
- “Evaluation of a New Propriety CAD/CAM Herbst-style Sleep Device” by Dr. Erika C. Mason, DDS, D-ABDSM, D-ACSDD.
- “Is the Relationship Between OAT Outcomes, Dosage and OAT Device Type as Expected? A Private Practice, Retrospective Cohort Study” by Dr. Rosemarie Rohatgi, DMD, D-ABDSM, D-ASBA, D-ABCDSM.
- “ Prevalence of Dental Sleep Medicine Patients at Increased Risk of Neurodegenerative Disease”, Levendowski D, Morgan T, Clark SJ, Hevener B, Cruz Arista D, Westbrook P.
- “Therapeutic Responses to Oral Appliance Therapy: Investigation of Two Criteria”, Munafo D, Clark SJ, Levendowski D, Hevener B, Cruz Arista D, Morgan T.
“We are proud that ProSomnus is supporting several posters at the AADSM this year by leading doctors in the field. These posters demonstrate what precision medical device manufacturing means to patient comfort, reduced risk of side effects, new product development and efficiency”, stated David Kuhns, PhD, CSO for ProSomnus Sleep Technologies. “Please meet with these doctors at their posters and come by our booth to learn even more about precision medical sleep devices.”
About ProSomnus Sleep Technologies
ProSomnus® Sleep Technologies designs, manufactures and markets FDA Cleared Class II Medical Devices for the treatment of Obstructive Sleep Apnea. Diagnosed by Medical Doctors and provided by Dentists, ProSomnus Devices are the first, precision oral appliance therapy devices designed to enhance compliance, mitigate side effects and, enable providers to achieve excellent patient experiences and outcomes. They have been used to treat thousands of patients, with clinical performance that has been validated in numerous studies.
Heather Whalen, VP Marketing